Dustri Online Services

Books: 0	Journals: 1	Articles: 3

Abstract

Allergologie select, Vol. 8/2024 (278-282)

Successful case of deferasirox slow desensitization in adults

Buket Basa Akdogan¹, Ilkay Koca Kalkan¹, Gozde Koycu Buhari¹, Ozlem Ozdedeoğlu¹, Hale Ates¹, Kurtulus Aksu¹, and Ferda Oner Erkekol²

¹University of Health Sciences Ataturk Chest Diseases and Chest Surgery Education and Research Hospital, and ²Yıldırım Beyazıt University, Division of Immunology and Allergy, Department of Chest Diseases, Ankara, Türkiye
Introduction: When deferasirox is used in iron chelation therapy, maculopapular rash occurs in 10% of patients, but there is no accepted and implemented protocol for the management of these drug reactions in adults. Case report: A 23-year-old woman diagnosed with thalassemia major is presented. She had taken 1,500 mg oral deferasirox for 1 week. Five hours after the last dose, a pruritic maculopapular rash developed on the body, face, and hands. The rash spread to the whole body within 3 days. The absolute necessity for the patient to take the drug was clarified by the hematology department. The patient’s history was evaluated. A delayed-type hypersensitivity reaction due to deferasirox was considered. Management: The slow desensitization protocol described in the literature and applied on a case-by-case basis in pediatric patients was modified to shorten the duration by determining appropriate doses for the current preparation. The desensitization process was started with 1/100,000 of the total dose and the therapeutic dose was reached with a 2- to 2.5-fold increase in dose. No pre-medication was applied. During the procedure, at a low dose of 0.1 mg, local flushing and erythema was observed around the auricle on the face. The reaction did not progress. Conclusion: Slow desensitization protocol for oral deferasirox was successfully applied in an adult patient.Correspondence to:
Buket Basa Akdogan, MD, Incirli st. No:57 Floor:3, 34147 Bakirkoy/Istanbul, Türkiye
Email: [email protected]

Abstract

Allergologie select, Vol. 10/2026 (49-51)

A case of herpes zoster following the first dose of benralizumab

Kurtuluş Aksu, Onur Telli, Melis Yağdıran, Fatma Dindar Çelik, Hatice Çelik Tuğlu, and Özge Göktürk

Division of Immunology and Allergy, Department of Chest Diseases, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkiye
Introduction: Biological agents used in the treatment of rheumatic diseases and malignancies cause an increase in herpes zoster susceptibility. This may also be the case for monoclonal antibody treatments used in asthma based on recent pharmacovigilance data. Case report: Herpetic lesions occurred on the anterior chest wall of a 43-year-old patient who was initiated on benralizumab treatment for severe eosinophilic asthma. The patient received diagnosis of herpes zoster and showed significant clinical improvement with oral valacyclovir treatment. Since it was not certain whether the herpes eruption was directly related to benralizumab treatment, benralizumab treatment was continued at the patient’s request and with the approval of the dermatology department. The patient did not experience recurrent herpes eruptions or any other clinical problems with the repeated doses given.Correspondence to:
Prof. Kurtuluş Aksu, MD, Professor in Allergy and Pulmonology, Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi, 06280, Keçiören, Ankara, Türkiye
Email: [email protected]

Abstract

Allergologie select, Vol. 10/2026 (98-100)

Does the teicoplanin skin test predict IgE-mediated hypersensitivity?

Nur Betül Baştuğ İnan, Özge Göktürk, Yavuz Karahan, and Kurtuluş Aksu

Division of Immunology and Allergy, Department of Chest Diseases, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Türkiye
Various delayed-type hypersensitivity reactions have been reported following teicoplanin administration, including drug rash with eosinophilia and systemic symptoms (DRESS syndrome), and acute generalized exanthematous pustulosis (AGEP). Until recently, IgE-mediated hypersensitivity reactions to teicoplanin were considered to be rare. However, reports of such reactions have increased in recent years. These case reports also suggest that teicoplanin skin testing can predict IgE-mediated hypersensitivity reactions. In the present case, teicoplanin skin prick and intradermal tests were negative, yet an immediate skin reaction occurred during provocation.Correspondence to:
Kurtuluş Aksu, MD, Professor in Allergy and Pulmonology, Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi, 06280, Keçiören, Ankara, Türkiye
Email: [email protected]

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail